» Articles » PMID: 8436350

Pathology of the Gastric Antrum and Body Associated with Helicobacter Pylori Infection in Non-ulcerous Patients: is the Bacterium a Promoter of Intestinal Metaplasia?

Overview
Journal Histopathology
Date 1993 Jan 1
PMID 8436350
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

A series of 115 consecutive, non-ulcerous, dyspeptic patients were examined for Helicobacter pylori (H. pylori) colonization in the gastric antral and/or body mucosa using Giemsa staining. Findings were correlated with the presence and degree of activity of superficial gastritis, deep gastritis, atrophic gastritis and with the presence of intestinal metaplasia. The prevalence of H. pylori positivity was 61.7%. In 59 of the 71 positive patients (83%), H. pylori was detected in the antrum or in both the antral and oxyntic mucosa. In the remaining 12 positive patients, H. pylori was detected only in the oxyntic mucosa nad in all these cases, the antrum showed intestinal metaplasia associated with atrophic gastritis (25%). In both antral and oxyntic mucosa, the activity of the gastritis was significantly correlated with H. pylori colonization. Linear logistic regression analysis showed that in patients with intestinal metaplasia the presence of H. pylori infection was significant in predicting the presence of more extensive intestinal metaplasia after adjusting for age. The prevalence of intestinal metaplasia types II and III was 65.5% in the H. pylori positive and 25% in the H. pylori negative patients. The antral mucosa is thought to be the elective site for H. pylori related histological lesions. At a later stage, H. pylori can be detected only in the oxyntic area while the antral mucosa shows extensive metaplastic or atrophic lesions. We would suggest that H. pylori plays a promotional role in the morphogenesis of intestinal metaplasia.

Citing Articles

Marked intestinal trans-differentiation by autoimmune gastritis along with ectopic pancreatic and pulmonary trans-differentiation.

Takeuchi C, Sato J, Yamamichi N, Kageyama-Yahara N, Sasaki A, Akahane T J Gastroenterol. 2023; 59(2):95-108.

PMID: 37962678 PMC: 10810929. DOI: 10.1007/s00535-023-02055-x.


Autoimmune gastritis.

Lenti M, Rugge M, Lahner E, Miceli E, Toh B, Genta R Nat Rev Dis Primers. 2020; 6(1):56.

PMID: 32647173 DOI: 10.1038/s41572-020-0187-8.


Previous Helicobacter pylori infection-induced atrophic gastritis: A distinct disease entity in an understudied population without a history of eradication.

Kishikawa H, Ojiro K, Nakamura K, Katayama T, Arahata K, Takarabe S Helicobacter. 2019; 25(1):e12669.

PMID: 31680399 PMC: 7003427. DOI: 10.1111/hel.12669.


Antibiotic dispensation rates among participants in community-driven health research projects in Arctic Canada.

Williams K, Colquhoun A, Munday R, Goodman K BMC Public Health. 2019; 19(1):949.

PMID: 31307422 PMC: 6631451. DOI: 10.1186/s12889-019-7193-3.


Therapeutic or spontaneous Helicobacter pylori eradication can obscure magnifying narrow-band imaging of gastric tumors.

Kobayashi M, Hashimoto S, Mizuno K, Takeuchi M, Sato Y, Watanabe G Endosc Int Open. 2016; 4(6):E665-72.

PMID: 27556076 PMC: 4993888. DOI: 10.1055/s-0042-105869.